CF
SAGE

Corebridge Financial’s Sage Therapeutics SAGE Stock Holding History

Corebridge Financial’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,760
Closed -$213K – 2267
2025
Q1 		$213K Sell
26,760
-397
-1% -$2.91K ﹤0.01% 2041
2024
Q4 		$147K Sell
27,157
-2,050
-7% -$12.5K ﹤0.01% 2346
2024
Q3 		$211K Buy
29,207
+239
+0.8% +$2.19K ﹤0.01% 2204
2024
Q2 		$315K Buy
+28,968
New +$371K ﹤0.01% 1939

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Corebridge Financial's SAGE Position: Q2 2025 in Review

Corebridge Financial sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 26,760 shares — an estimated $213K sold.

Corebridge Financial first reported a position in SAGE in Q2 2024 and held it in 4 quarters. The position peaked at $315K in Q2 2024. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Corebridge Financial reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 26,760 Sage Therapeutics shares in Q2 2025, an estimated $213K.
  • Corebridge Financial first reported a position in Sage Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Sage Therapeutics position peaked at $315K in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.